Frequency of CD4+ FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 859-864

  Fujioka, T ^a   Tamaki, H ^a   Ikegame, K ^a   Yoshihara, S ^a   Taniguchi, K ^a   Kaida, K ^a   Kato, R ^a   Inoue, T ^a   Nakata, J ^a   Ishii, S ^a   Soma, T ^a   Okada, M ^a   Ogawa, H ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

allogeneic SCT; GVHD; HLA mismatch; regulatory T cells

Indexed keywords

CD4 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FLOW CYTOMETRY; HLA MATCHING; HUMAN; IMMUNOLOGICAL PARAMETERS; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGULATORY T LYMPHOCYTE; REGULATORY T LYMPHOCYTE CD4+ T LYMPHOCYTE RATIO; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ADULT; ALLOGRAFTS; CD4 LYMPHOCYTE COUNT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INCIDENCE; MALE; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 84879069945     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.232     Document Type: Article

References (39)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
2. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4\+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253.
3. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(\+)CD25(\+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
4. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(\+)CD25(\+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
5. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(\+)CD25(\+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
6. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S et al. Reduced frequency of FOXP3\+ CD4\+CD25\+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-2911.
7. Meignin V, Peffault de Latour R, Zuber J, Regnault A, Mounier N, Lemaitre F et al. Numbers of Foxp3-expressing CD4\+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33: 894-900.
8. Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F et al. Kinetic of regulatory CD25high and activated CD134\+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697-703.
9. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
10. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4\+CD25\+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
11. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297.
12. Zhai Z, Sun Z, Li Q, Zhang A, Liu H, Xu J et al. Correlation of the CD4\+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transpl Int 2007; 20: 440-446.
13. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M et al. Frequency of CD4(\+)CD25(hi)FOXP3(\+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16: 907-914.
14. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, Keyvanfar K et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010; 116: 1165-1171.
15. Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 2003; 17: 2052-2054.
16. Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008; 36: 1-8.
17. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073-1084.
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
20. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007; 85: 154-162.
21. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
22. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-344.
23. Duran-Struuck R, Reddy P. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2008; 85: 303-308.
24. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539-1542.
25. Willems E, Humblet-Baron S, Dengis O, Seidel L, Beguin Y, Baron F. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplant 2010; 45: 1442-1448.
26. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003; 9: 292-303.
27. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte Jr J et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 1882-1891.
28. Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297-302.
29. Sakai R, Maruta A, Yanoma S, Shimizu A, Harada M, Nakamura Y et al. Effect of sublethal total body irradiation on acute graft-versus-host disease and graftversus-leukemia effect in SCID mice. Bone Marrow Transplant 1997; 20: 183-189.
30. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versushost disease. J Exp Med 1992; 175: 405-413.
31. Schneider M, Munder M, Karakhanova S, Ho AD, Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4\+CD25\+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol 2006; 28: 382-390.
32. Korngold R, Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 1985; 135: 3004-3010.
33. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106: 1113-1122.
34. Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E et al. Donor CD4\+T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Exp Hematol 2007; 35: 155-163.
35. Yu XZ, Albert MH, Anasetti C. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J Immunol 2006; 176: 3383-3390.
36. Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, Marijt EW, Kruisselbrink AB, Frederik Falkenburg JH et al. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA class I causing severe acute GVHD. Biol Blood MarrowTransplant 2012; 18: 210-219.
37. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A et al. Regulatory T cells inhibit stable contacts between CD4\+T cells and dendritic cells in vivo. J Exp Med 2006; 203: 505-511.
38. Huang YH, Sojka DK, Fowell DJ. Cutting edge: regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-kappaB nuclear accumulation in CD4 T cells. J Immunol 2012; 188: 947-951.
39. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.